(Q38458853)

3 September 2017

1 reference

title

Dinutuximab: first global approval (English)

1 reference

3 September 2017

1

Sohita Dhillon

1 reference

3 September 2017

publication date

1 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

75

1 reference

3 September 2017

issue

8

1 reference

3 September 2017

page(s)

923-927

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-015-0399-5

3 September 2017

exact match

0 references

cites work

Development of treatment strategies for advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Treatment of high-risk neuroblastoma with anti-GD2 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0399-5

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients

21 January 2018

1 reference

12 December 2020

Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells

1 reference

12 December 2020

Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

1 reference

12 December 2020

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

1 reference

12 December 2020

Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

1 reference

12 December 2020

Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma

1 reference

12 December 2020

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

12 December 2020

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

12 December 2020

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients

1 reference

12 December 2020

Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma

1 reference

12 December 2020

10.1007/S40265-015-0399-5

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1028838509

0 references

1 reference